Hematopoietic and lymphoid system neoplasm

This study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with…

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…

This early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the …

This study tests a new drug, AZD9829, in people with blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD123 found on cancer cells. The main goals are to find a safe dose and check for side effects. About 56 adults will take…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…

This study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…

This study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…

This study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the …

This Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherap…

This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…

This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …

This phase 1 trial tested a personalized DNA vaccine in 9 patients with a rare, slow-growing blood cancer called lymphoplasmacytic lymphoma. The vaccine was made from each patient's own cancer cells and designed to help the immune system recognize and attack the cancer. The main …

This study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…

This phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…

This study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…

This phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…

This study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …

This phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…

This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…

This study tested a drug called ixazomib, alone or with other medicines, in 165 people whose multiple myeloma (a blood cancer) had come back. The goal was to see if these combinations could shrink or control the cancer. Participants received different treatment plans, and doctors…

This study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…

This phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…

This trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…

This phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell …

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…

This study tested a daily pill called E7820 in 12 adults with relapsed or treatment-resistant acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. All participants had specific mutations in splicing factor genes. The goal was to see if the drug c…

This completed trial tested a herbal ointment made from Syzygium formosum leaves in 90 people with mild to moderate atopic dermatitis (eczema). The ointment was compared to standard moisturizers to see if it was safe and effective. The study measured skin severity, water loss, an…

This study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This study looked at whether denosumab, a drug usually used for bone health, could safely reduce the risk of smoldering multiple myeloma turning into active multiple myeloma. Twenty people with smoldering multiple myeloma took part. The goal was to see if the drug could lower the…

This study tested a treatment called tisagenlecleucel, a type of CAR-T cell therapy, in 98 adults with follicular lymphoma that had come back or stopped responding to other treatments. The therapy works by reprogramming a patient's own immune cells to find and attack cancer cells…

This early-phase study tested a combination of two drugs, daratumumab and ibrutinib, in 15 people with untreated chronic lymphocytic leukemia (CLL) who needed therapy. The goal was to see if the combination is safe and how well it works at controlling the disease. Participants re…

This early-phase trial tested two drugs, lenalidomide and idelalisib, in 8 people with follicular lymphoma that had returned after previous treatment. Lenalidomide helps the immune system fight cancer, while idelalisib blocks enzymes that cancer cells need to grow. The main goal …

This study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused …

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…

This study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involve…

This study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…

This phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on mainta…

This phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and r…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…

This study tested whether measuring oxygen levels in the blood (ScvO2) can help doctors decide when to give blood transfusions to anemic patients after heart surgery. 100 patients were randomly assigned to receive transfusions based on standard guidelines or only if their ScvO2 w…

This phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…

This Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This Phase 3 trial tested whether the CAR-T cell therapy tisagenlecleucel works better than standard treatments for adults with aggressive B-cell non-Hodgkin lymphoma that came back or didn't respond to initial therapy. The study enrolled 330 participants and compared how long th…

This phase 3 study tested an oral drug called azacitidine (CC-486) against standard treatments in 93 adults with a rare T-cell lymphoma that had relapsed or stopped responding. The main goal was to see if the drug could delay cancer progression or death. Participants were randoml…

This phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles…

This phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…

This study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free …

This study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.

This phase 3 study tested whether the drug daratumumab, given as a shot under the skin, could delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. 390 people with high-risk smoldering myeloma were randomly assigned to receive daratumumab or to b…

This study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease…

This phase 2 trial tested a combination of two drugs, ibrutinib and blinatumomab, in 19 adults with B-cell acute lymphoblastic leukemia that had come back or wasn't responding to treatment. The goal was to see how many patients achieved complete remission. The study is completed,…

This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…

This study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs.…

This early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein c…

This early-phase trial tested whether adding the drug uproleselan to standard chemotherapy (cladribine and low-dose cytarabine) could help people with treated secondary acute myeloid leukemia (AML). Secondary AML is a type of leukemia that develops after treatment for another bon…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This study tested a new formulation of two chemotherapy drugs (CPX-351) in 56 adults with newly diagnosed acute myeloid leukemia (AML) who were at high risk of not responding to standard treatment. The goal was to find the best dose and see how well it worked to stop cancer cells…

This study tested whether regular infusions of Panzyga (a concentrated antibody solution from donated blood) could prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The trial included 247 adults with CLL who were recei…

This early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…

This study tested a combination of brentuximab vedotin and AVD chemotherapy in 118 adults with newly diagnosed, early-stage Hodgkin lymphoma that is considered unfavorable. The goal was to see if this treatment could cure more patients while reducing long-term side effects, espec…

This phase II trial studied how well surgery, chemotherapy, and radiation work in 188 children with newly diagnosed, low-stage lymphocyte predominant Hodgkin disease. The goal was to find effective treatments that minimize side effects. Patients received different therapies based…

This phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …

This study tested a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal was to see if the drugs cou…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…

This study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it …

This large phase III trial tested whether adding the targeted drug dasatinib to standard chemotherapy improves outcomes for children and young adults with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL), including those with certain genetic mutations. Nearly…

This phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if t…

This early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…

This study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…

This early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

This completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients receiv…

This study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants too…

This large phase III trial tested whether adding the drugs bortezomib and sorafenib to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. Over 1,600 participants took part. The study focused on patients w…

This phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study tested a new combination treatment for people with a type of blood cancer (B-cell non-Hodgkin's lymphoma) that did not respond to standard therapies. The treatment combined a drug (XPO-1 inhibitor) with specially engineered immune cells (CAR-T cells). The goal was to s…

This phase 3 study tested whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, dexamethasone) helps people with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. The main goal was to see if more patients achieve a …

This study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…

This study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…

This pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…

This early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…

This phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had …

This phase 2 trial tested a drug called zilovertamab vedotin (MK-2140) in 140 people with diffuse large B-cell lymphoma that had returned or stopped responding to at least two prior treatments. The goal was to see how many patients had their tumors shrink or disappear. The study …

This large phase 3 trial enrolled over 9,000 children with newly diagnosed standard-risk B-ALL or localized B-LLy. Researchers tested different combinations and doses of chemotherapy drugs to see which worked best with the fewest side effects. The goal was to improve disease-free…

This early-phase trial tested a drug called ONC-201 in 20 people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who had recently received a stem cell transplant. Participants took the drug by mouth once a week for a year to see if it was safe and co…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side eff…

This study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…

This early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This phase 2 trial tests whether a combination of clofarabine and intermediate-dose cytarabine (CLARA) works better than high-dose cytarabine (HDAC) alone as consolidation therapy for younger adults (18-60) with newly diagnosed acute myeloid leukemia (AML). After initial remissio…

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…

This early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …

This study tested a treatment plan for adults aged 65 to 80 with a type of lymphoma (large B-cell). The plan combined standard chemotherapy with targeted antibodies and a radioactive drug. The goal was to see if this approach could better control the cancer. The study involved 30…

This phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see how many patients achieved complete remission. The approach aims to improve outcomes by targe…

This early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…

This study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…

This study tested a three-drug combination (navitoclax, venetoclax, and decitabine) in 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to standard therapy. The goal was to find the safest dose and see if the combo could shrink or control th…

This study looked at whether adding focused radiation (SBRT) or surgery to standard treatments like chemo or hormone therapy helps people with breast cancer that has spread to just one or two places. 129 participants were randomly assigned to get standard care alone or standard c…

This early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …

This study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…

This early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…

This study looked at 88 adults in China with lower-risk myelodysplastic syndromes (MDS) who had not received prior treatment with erythropoiesis-stimulating agents. They were given luspatercept, and researchers tracked how many became free from red blood cell transfusions and whe…

This study tested a treatment called anti-BCMA CAR T-cell therapy in 40 adults with multiple myeloma whose disease did not respond well enough to a stem cell transplant and maintenance therapy. The goal was to see if this one-time cell therapy could help more patients achieve a c…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with relapsed or hard-to-treat Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma. The goal was to …

This study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researcher…

This early-phase study tested the safety of the drug blinatumomab (Blincyto®) in 6 Japanese adults newly diagnosed with a type of leukemia called B-ALL. The main goal was to see what side effects occurred. Researchers also looked at how the drug moves through the body and whether…

This phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…

This completed study looked at the safety of Calquence (acalabrutinib) capsules in 67 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Researchers tracked side effects like infections and bone marrow problems during everyday use. …

This study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This early-phase study tested whether adding two targeted drugs, gemtuzumab ozogamicin and midostaurin, to standard chemotherapy is safe for people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that has a FLT3 mutation. The trial enrolled 21 adults and a…

This early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug l…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a drug called ustekinumab in 8 people with a rare, severe form of Behçet's syndrome affecting the gut, along with a blood disorder called myelodysplastic syndrome. The goal was to see if the drug could control gut symptoms and reduce disease activity over 24 wee…

This study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs …

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …

This phase 1 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 patients whose acute myeloid leukemia or myelodysplastic syndrome came back or did not respond after a donor stem cell transplant. The goal was to find the safest dose and see if the drugs could he…

This phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…

This study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed tha…

This early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …

This early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and…

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…

This study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting w…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study tested whether a special oral nutritional supplement (Ensure Complete) could help patients with blood cancer maintain weight and gut health after a stem cell transplant. One hundred participants were randomly assigned to receive either the supplement or a standard hosp…

This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…

This early-phase study tested a new drug called siremadlin added to two existing drugs (venetoclax and azacitidine) for adults with acute myeloid leukemia (AML) who are too frail for standard chemotherapy. The study included 14 people whose cancer did not respond well to initial …

This phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy…

This study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatments. The goal was to see if the drug pair could shrink tumors. The …

This early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…

This study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusio…

This large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…

This early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…

This study tested an experimental pill called Bomedemstat in 73 people with essential thrombocythemia, a rare blood condition causing too many platelets. Participants had already tried at least one standard treatment without success. The main goals were to check safety and see if…

This study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…

This study tested a drug called luspatercept in 30 adults from China and Japan who have a bone marrow disorder (MDS) and need regular red blood cell transfusions. The goal was to see if the drug could help them go without transfusions for at least 8 weeks. The drug works by helpi…

This study tested different dosing schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to see if changing the dose or how often it is given could reduce serious eye…

This early-stage study tested a new drug called LYT-200 in 101 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had come back or stopped responding to treatment. The main goals were to check the drug's safety and find the right dose. While not…

This study tested a new way to deliver total body radiation to adults with blood cancers who need a stem cell transplant. The goal was to see if this method could effectively target cancer while protecting the lungs. 36 patients took part, and the study focused on safety and how …

This study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.

This study tested a new drug called ABC008 in 21 adults with T-cell large granular lymphocytic leukemia (T-LGLL), a rare blood cancer. The drug was given as a shot under the skin. The main goal was to check for side effects and see how the drug affects blood counts and other lab …

This early-phase trial tested whether high-dose chemotherapy followed by a stem cell transplant is safe and feasible for 25 people with HIV who also have lymphoma. The goal was to see how well the body recovers and to monitor side effects. Results could point to a new treatment p…

This study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…

This early-phase trial tested a combination of two drugs, enasidenib and cobimetinib, in just 3 patients with a specific form of acute myeloid leukemia (AML) that had come back or didn't respond to treatment. The goal was to see if the combination was safe and to find the best do…

This study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…

This early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…

This study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to con…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This early-stage trial tested an oral drug called NTX-301 in 22 adults with certain blood cancers (MDS, AML, or CMML) that had not responded to prior treatments. The main goal was to check safety and find the right dose. Researchers also looked for signs that the drug might help …

This study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This study tested a combination of chemotherapy drugs in 318 adolescents and young adults (ages not specified but typically 15-39) with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see how well the treatment worked at killing cancer cells and stopping the d…

This completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …

This phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…

This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …

This Phase 2 study tested avapritinib, a daily tablet that targets a specific genetic mutation, in 107 people with advanced systemic mastocytosis (a rare blood cancer). The main goal was to see how many patients had their tumors shrink or symptoms improve. Results suggest the dru…

This phase 2 trial tested the antibiotic doxycycline as a first treatment for a rare type of eye lymphoma (OAMZL) that may be linked to a bacterial infection. 44 newly diagnosed patients took doxycycline for several months. The goal was to see if eradicating the infection could c…

This study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effec…

This study tested a new approach for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. Researchers gave patients a special type of immune cell called cytokine-induced memory-like natural killer (CIML NK) cells, along with donor immune …

This early-stage trial tested the safety of a drug called duvelisib when given with either romidepsin or bortezomib for adults with T-cell lymphoma that returned or didn't respond to prior treatment. The study involved 114 participants and aimed to find the highest safe dose. Thi…

This study tested a combination of four drugs (acalabrutinib, bendamustine, rituximab, and cytarabine) as a first treatment for people with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach could safely improve remission rates before a stem cell tran…

This study tested a new combination of chemotherapy drugs for children and young adults with acute lymphoblastic leukemia (ALL) that had returned or not responded to first treatment. The goal was to find the safest dose of clofarabine when given with other medicines. Twenty parti…

This phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to ad…

This early-phase study tested a two-drug combination (pevonedistat plus decitabine) in 12 people with high-risk acute myeloid leukemia (AML), including those who had relapsed or couldn't tolerate standard chemo. The main goal was to find the safest dose and identify side effects.…

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This study looked at whether Vidaza, a drug used for acute leukemia, could also help treat atrial fibrillation (an irregular heartbeat). The idea was that Vidaza might reverse certain DNA changes that lower the activity of a gene important for heart function. Only one person took…

This phase 2 trial tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep remission (stringent co…

This study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete response…

This study looked at whether giving vitamin D supplements to people with low vitamin D levels and newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia could improve their outcomes. About 197 participants received either a low or high dose of vitamin D while underg…

This phase 2 study tested a combination of two drugs, bendamustine and rituximab, in 27 people with relapsed or progressive marginal zone B-cell lymphoma. The goal was to see how well the treatment shrank or controlled the cancer. Participants had already tried at least one prior…

This early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…

This Phase 3 trial tested an oral chemotherapy drug, azacitidine, against standard treatments in 86 patients with a rare type of T-cell lymphoma that had returned or not responded to prior therapy. The main goal was to see if the oral drug could delay cancer progression. The stud…

This early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…

This study tested a new drug called HX009 in 48 Chinese patients with lymphoma that had relapsed or not responded to prior treatments. HX009 is a dual-target antibody designed to block two proteins (CD47 and PD-1) that help cancer cells hide from the immune system. The goal was t…

This early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…

This early-phase study tested whether adding the targeted drug palbociclib to standard chemotherapy is safe for children with acute lymphoblastic leukemia that has returned or not responded to treatment. Only 2 children took part, and the main goal was to find the highest tolerab…

This study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received low-dose radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…

This study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This study offers continued treatment with elotuzumab (plus dexamethasone) to 67 multiple myeloma patients who were already benefiting from it in earlier trials. The main goal is to keep providing the drug and track how long patients stay on treatment. Researchers will also monit…

This early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This phase 2 study tested whether the drug romiplostim can prevent severe low platelet counts caused by chemotherapy in people with lymphoma. Eleven adult patients received weekly injections of romiplostim during their 21-day chemo cycles. The goal was to see if it could reduce t…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This early-stage trial tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug by IV or injection, and resea…

This study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…

This study tested a new drug, crenolanib, against the standard drug midostaurin in adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). All 214 participants received standard chemotherapy and, if eligible, a bone marrow transplant, plus one of the two…

This phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…

This Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had n…

This study tested a combination of two drugs, azacitidine and venetoclax, in 42 elderly patients (age 60+) with newly diagnosed acute myeloid leukemia (AML) who could not have standard chemotherapy. The treatment was given as an initial 'induction' phase, followed by a 'maintenan…

This study tested whether adding the drug crenolanib to standard chemotherapy helps adults up to age 75 with a hard-to-treat form of acute myeloid leukemia (AML) that has a specific genetic change (FLT3 mutation). Participants received either crenolanib or a placebo alongside che…

This study tested a treatment called KTE-X19, a type of CAR T-cell therapy, in 95 children and adolescents whose B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) had returned or stopped responding to standard treatments. The therapy involves collecti…

This phase 2 trial tested a combination of drugs called VR-CAP (bortezomib, rituximab, and chemotherapy) as a first treatment for people with marginal zone lymphoma, a rare blood cancer. 26 patients received up to 6 cycles of treatment. Researchers measured how long patients live…

This study tested a program to help children with acute lymphoblastic leukemia (ALL) take their daily chemotherapy medication (mercaptopurine) as prescribed during maintenance therapy. 570 children in remission were randomly assigned to either the intervention program or standard…

This phase 1b trial tested the safety of adding TAK-079 (Mezagitamab) to standard treatments for 50 people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal was to find the right dose and watch for side effects. Researchers also tracked how we…

This early-phase trial tested an experimental drug called OPB-111077 combined with two standard chemotherapy drugs (bendamustine and rituximab) in 36 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goal was to check the safety…

This study tested adding lenalidomide (Revlimid) to standard chemotherapy (RICE) for people with relapsed diffuse large B-cell lymphoma. The goal was to see if the combination is safe and can improve response rates, helping more patients qualify for a stem cell transplant. Only 1…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease no longer responded well to standard JAK-inhibitor treatment. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need…

This study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take the usual strong chemotherapy. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy against another commo…

This phase II trial tested whether a newer antibiotic combination (imipenem-relebactam) works better than standard antibiotics for treating fever caused by low white blood cell counts in cancer patients. About 100 adults with cancer or who had a stem cell transplant took part. Th…

This study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested a drug called CT-011 (a PD-1 blocker) and a dendritic cell vaccine given after a stem cell transplant in 35 people with multiple myeloma. The goal was to see if this combination is safe and can boost the immune system to fight remaining cancer cells. Researchers…

This study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…

This study looked at 180 people with rectal cancer that had spread to lymph nodes in the pelvis. One group received a three-drug chemotherapy regimen (FOLFOXIRI) followed by surgery to remove the affected lymph nodes. The other group got standard chemoradiotherapy before surgery.…

This phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how we…

This study tested a combination of two drugs, Rituxan and Imprime PGG, in 25 people with a slow-growing type of lymphoma that had come back or not responded to prior treatment. The goal was to see if the combination could shrink tumors and control the disease. Results focused on …

This phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…

This phase 2 trial tested whether giving the targeted drug ibrutinib along with standard vaccines (pneumonia, flu, and Tdap) can help people with early-stage, high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay progression-free longer. The study …

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …

This study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…

This study tested a drug called GO-203-2C, which targets a protein (MUC1) found on cancer cells while sparing healthy cells. It was given alone or with another drug (decitabine) to 33 adults with acute myeloid leukemia that had returned or not responded to treatment. The main goa…

This study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…

This early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene edi…

This study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…

This study looked at 124 adults with chronic myeloid leukemia (CML) who had been on the drug nilotinib for at least 3 years and had very low levels of cancer. First, researchers tested if lowering the nilotinib dose by half for a year could help patients stop treatment entirely. …

This study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …

This study tested an oral drug called ASTX727 in people with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder. The goal was to see if a lower dose given over a longer schedule could improve blood cell counts and reduce the need for transfusions. The trial enroll…

This study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…

This early study tested a new radioactive tracer called 99mTc-1-thio-D-glucose in 16 adults with Hodgkin or non-Hodgkin lymphoma. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it went in the body. The goal was to check safety and whether the …

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…

This study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent he…

This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…

This completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…

This study tested a new rapid test that checks for thyroid cancer spread to neck lymph nodes in just minutes, instead of the usual days-long wait. Researchers studied 250 adults with suspected or known thyroid cancer, comparing the quick test to standard lab methods. The goal was…

This study tested new adhesive sensors that stick to the skin to see if they can detect early signs of lymphedema, a painful arm swelling that can happen after cancer treatment. Researchers compared readings from 76 people with and without lymphedema. The goal is to create a simp…

This early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells.…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This study tested a drug called abatacept, given as a shot under the skin, to prevent a serious complication called graft-versus-host disease (GVHD) in 29 adults with blood cancers. Participants received a stem cell transplant from a half-matched donor. The goal was to see if aba…

This study tested whether fosfomycin, an older antibiotic, works as well as ciprofloxacin for preventing serious infections in people with blood cancers like leukemia or those receiving a stem cell transplant. 177 adults from 11 Spanish hospitals took part. The main goal was to s…

This study tested whether sending text message reminders to parents could increase routine vaccination rates in children aged 0-2 years. Over 1,000 families in Brooklyn, New York, whose children were behind on vaccines received texts when shots were due or coming due. The goal wa…

This phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…

This study is testing a new type of prosthetic leg for children aged 3 to 18 that can be easily adjusted as they grow. The device is designed to be fitted in a single session and adjusted by the wearer. Researchers will measure comfort, socket pressure, walking speed, and quality…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study looked at 72 children aged 10-18 who finished chemotherapy for acute lymphoblastic leukemia. Researchers compared two types of aerobic exercise—one with a steady intensity and one that gradually increases—to see which better improves heart and lung fitness. All kids ex…

This trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …

This study tested whether young cancer survivors (ages 15-39) could learn to do acupressure on themselves to reduce fatigue. 42 people who had finished cancer treatment at least three months ago and still felt tired took part. They used a special tool and a phone app to apply pre…

This study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …

This study looked at whether having a tendency toward depression affects how well people with thymoma-associated myasthenia gravis (MG) respond to psychological counseling. Nineteen adults who had surgery for thymoma and MG received eight sessions of counseling based on Gestalt t…

This study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…

This study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on cer…

This study looked at whether a type of talk therapy called cognitive-behavioral therapy (CBT) can help reduce the severe tiredness that many people feel after a stem cell transplant for blood cancer. 66 adults who had a transplant at least 6 months earlier and still had significa…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…

This study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…

This study tested a 10-week progressive adapted physical education program for 46 adolescents with mild intellectual disability. Half did the special program plus regular school activities, while the other half stuck to their usual curriculum. Researchers measured upper-body stre…

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This study tested whether adding virtual reality (VR) nature experiences to standard treatment helps adults with mild to moderate depression feel better. 45 participants were split into three groups: one used a high-end VR lab setup, another used a simple self-managed VR, and a c…

This study tested a 12-week online program called Brain Health Together for older adults with mild cognitive decline. Participants joined live-streaming exercise and education classes, plus individual coaching, all from home. The goal was to see if the program could improve think…

This study tested whether an adapted form of Narrative Exposure Therapy (NET) is acceptable and helpful for adults with mild learning disabilities who have experienced trauma. Thirteen participants completed the therapy, which involved talking through their life events in a struc…

This study tested a structured educational program called the Myeloma Pack for people with multiple myeloma. The goal was to see if it could reduce anxiety and depression and improve quality of life. 85 patients took part while receiving standard cancer treatment. Researchers mea…

This study tested a web platform designed for people with mild cognitive impairment or mild to moderate dementia and their primary caregivers. The platform offers social networks, activities, and games to improve quality of life and help them stay in the community longer. Researc…

This study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…

This study tested a program to help stem cell transplant survivors who have sexual problems. Participants met with a nurse for three months and got educational materials. The goal was to see if this improved their sexual satisfaction, quality of life, and mood. The study involved…

This pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…

This study tracks 50 people with blood cancers who are receiving CAR T therapy. Researchers will take blood samples over time to measure immune cells and genetic changes. The goal is to find patterns that predict or explain why the cancer comes back. This is an observational stud…

This study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…

This completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…

This study follows 1,000 people with CD30-positive lymphoma who are already receiving or about to receive brentuximab vedotin as part of their normal care. Researchers will track side effects and how the drug is used in everyday practice, without giving any new treatment. The goa…

This study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…

This study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effec…

This completed study looked at how the drug opemalirsen (AZD2373) is processed in people with different levels of kidney function. Researchers gave a single injection to 35 adults, some with kidney impairment and some with healthy kidneys. The goal was to compare drug levels and …

This completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …

This completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to und…

This study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…

This study looked at 51 women who had a stem cell transplant for acute leukemia as adults. Researchers wanted to find out how many had gynecological problems like early menopause, vaginal graft-versus-host disease, or cervical issues two years after transplant. They also checked …

This pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…

This early-phase trial tested whether adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy is safe and reaches effective levels in the blood. It involved 26 children and young adults (ages 1 month to 21 years) newly diagnosed with acute myeloid le…

This study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …

This study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…

This study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…

This completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these …

This study looks at how the adrenal glands work in people who are critically ill, such as those with sepsis. Adrenal insufficiency may affect up to 77% of ICU patients, but current tests are not reliable. Researchers will measure hormone levels in 225 participants, including heal…

This study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.

This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…

This study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …

This study looked at 148 children with T-cell acute lymphoblastic leukemia to see if a high-tech gene test could find tiny amounts of cancer left after treatment. Researchers used next-generation sequencing to check for specific gene changes in immune cells. They then compared th…

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…

This study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…

This study examined whether PET scans can help doctors better stage mantle cell lymphoma and predict how patients will fare, compared to standard CT scans and bone marrow biopsies. Researchers analyzed data from 200 patients who had already completed a clinical trial. The goal wa…

This study looked back at 633 people with primary mediastinal large B-cell lymphoma (PMBCL) treated in Italy between 2007 and 2019. Researchers collected data on how well treatments worked, how many patients had disease that didn't respond or came back early, and survival rates. …

This study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…

This study collected blood, saliva, and eye fluid samples from 343 people with uveitis, an inflammatory eye disease that can cause vision loss. Researchers aimed to learn which genes and other factors might lead to the disease and affect treatment response. Participants were foll…

This study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…

This study looked back at medical records of 100 adults with multiple myeloma that had returned after initial treatment. Researchers compared how long patients stayed cancer-free on four different three-drug combinations. The goal was to see which combination worked best in real-…

This study followed over 900 newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Researchers compared heart-related side effects between those treated with lenalidomide (Revlimid) and those receiving other treatments. The goal was to better…

This completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This completed study in Japan looked at how low-risk myelodysplastic syndrome (MDS) or unexplained anemia affects patients' daily lives. Researchers used questionnaires and interviews with 56 participants to understand symptoms, quality of life, and unmet needs. The goal was to c…

This completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understan…

This study looked at how kidney function and race/ethnicity affect the drug treosulfan in 20 patients with AML or MDS getting a stem cell transplant. The goal was to find safe doses for those with kidney problems. It was a small, early-phase study that did not test a new treatmen…

This study looked at the tiny organisms (bacteria and fungi) living in the mouth and nose of children with leukemia or those getting a bone marrow transplant. Researchers wanted to see how these germ communities change during chemotherapy. The goal was to learn more, not to test …

This study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…

This study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…

This pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study looked at medical records from over 2,700 people in Japan with a type of lymphoma (B-cell non-Hodgkin's lymphoma) who were treated with Rituximab Pfizer. The goal was to see how often infections and other side effects happened, and to compare these results with those f…

This study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…

This study gave 6 healthy men a single dose of a radioactive form of the experimental drug DZD8586. The goal was to see how the drug moves through the body, how it is broken down, and how it leaves the body in urine and stool. This information helps researchers understand the dru…

This study looked at a different way to help children breathe during surgery. Instead of placing the breathing tube all the way into the windpipe, doctors placed it just above the vocal cords. The goal was to see if this method is easy, safe, and works well. The study included 85…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and their doctors communicate better and make decisions together. It involved 161 participants aged 60 and older. The goal was to see if the tool improved shared de…

This study looked at how a single dose of the drug AZD2693 moves through the body in people with liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood to understand safety and processing differences. A total of 35 adults took part. The goa…

This study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…

This study looked at whether a new educational program helps doctors-in-training better recognize and respond to child maltreatment. 84 medical residents from Canadian universities took part. The program was delivered either in a group with a leader or on their own. The goal was …

This study looked at whether children and teens who had a stem cell transplant for leukemia could use an iPad-based brain-training program. The main goal was to see if the program was practical and if kids would stick with it. Only 17 participants were enrolled, and the study foc…

This study reviewed medical records of 431 people with smoldering multiple myeloma (SMM), a pre-cancerous condition, to see how the disease progresses over time. Researchers looked at which patients are at higher risk of developing active multiple myeloma and what treatments they…

This study tested a new ultrasound technique to see the smallest blood vessels in lymph nodes on the neck. Researchers wanted to know if this method could tell the difference between healthy and cancerous lymph nodes. Twenty adults with head and neck cancer, lymphoma, or healthy …

This study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…

This completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolis…

This study looked at whether exercise training can improve physical capacity and heart function in adults who survived Hodgkin lymphoma after chemotherapy and chest radiation. Forty survivors took part in fitness tests and heart monitoring. The goal was to see if exercise could r…

This study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…

This study looked at whether it's possible to measure muscle mass and physical function in children (ages 8-21) with newly diagnosed solid tumors or lymphoma during cancer treatment. Researchers used simple tests like a 6-minute walk and a special drink to measure muscle, along w…

This completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This early-stage study tested the safety and tolerability of a new drug called EP395 in 78 healthy adults aged 18-65. Participants received either EP395 or a placebo capsule, and researchers monitored side effects, vital signs, and hearing. The goal was to find a safe dose range …

This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising …

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study tested a virtual reality (VR) afterschool program for 32 children ages 9-17. The goal was to see if kids would use and enjoy the VR system, and to measure their physical activity. This was a pilot study to gather information, not to treat or cure any disease.

This study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…

This study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…

This study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…

This study looked at how common iron deficiency is in cancer patients starting chemotherapy. Researchers checked iron levels in 480 adults with solid tumors or lymphoma. The goal was to find out how many patients might benefit from iron injections, without using other drugs like …

This pilot study tested a communication tool called UR-GOAL in 15 older adults (age 60+) with newly diagnosed acute myeloid leukemia (AML), along with their caregivers and doctors. The tool helps patients share their preferences and goals, so treatment decisions better match what…

This study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This completed study looked at how well COVID-19 vaccines trigger an immune response in children and young adults (under 24) with cancer or who had a transplant or cellular therapy. Researchers measured antibody and T-cell levels after vaccination. The goal was to learn more abou…

This study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at 182 older adults with blood cancer or lung cancer to see if a special calculator could predict who would have severe side effects from chemotherapy. Researchers measured patients' fitness before and after treatment to better understand how well they could han…

This study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looked at whether cancer survivors living in rural areas can create their own survivorship care plans and learn from telehealth education. 261 survivors of breast, colorectal, lung, lymphoma, or prostate cancer took part. The goal was to see if this approach improves t…